
    
      Patients in group A will receive 4 cycles of DC-CIK treatments within 8 months. Patients in
      group B will have no immunotherapy. Chemotherapy are available in both groups.The
      investigators want to evaluate the efficacy of combination of DC-CIK with chemotherapy in
      patients with treatment-refractory solid tumors.
    
  